Wordt geladen...

SAT-097 Weight Loss With Liraglutide 3.0 Mg Versus Placebo For Individuals Who Adhere To The Trial Drug: A Secondary Analysis From SCALE IBT

The objective of the SCALE IBT trial (NCT02963935) was to compare the weight loss of liraglutide 3.0 mg, a medication approved by the Food and Drug Administration for chronic weight management, to placebo, both in combination with 56 weeks of intensive behavior therapy (IBT) (i.e. reduced calorie in...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:J Endocr Soc
Hoofdauteurs: Shaw Tronieri, Jena, Wadden, Thomas, Sugimoto, Daniel, Lund, Michael, Auerbach, Pernille, Endahl, Lars, Rubino, Domenica
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Endocrine Society 2019
Onderwerpen:
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6552310/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SAT-097
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!